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Common variants in the transcription factor 7-like 2 (TCF7L2) gene have been identiﬁed as the strongest gen-
etic risk factors for type 2 diabetes (T2D). However, the mechanisms by which these non-coding variants
increase risk for T2D are not well-established. We used 13 expression assays to survey mRNA expression
of multiple TCF7L2 splicing forms in up to 380 samples from eight types of human tissue (pancreas, pancrea-
tic islets, colon, liver, monocytes, skeletal muscle, subcutaneous adipose tissue and lymphoblastoid cell
lines) and observed a tissue-speciﬁc pattern of alternative splicing. We tested whether the expression of
TCF7L2 splicing forms was associated with single nucleotide polymorphisms (SNPs), rs7903146 and
rs12255372, located within introns 3 and 4 of the gene and most strongly associated with T2D. Expression
of two splicing forms was lower in pancreatic islets with increasing counts of T2D-associated alleles of
the SNPs: a ubiquitous splicing form (P 5 0.018 for rs7903146 and P 5 0.020 for rs12255372) and a splicing
form found in pancreatic islets, pancreas and colon but not in other tissues tested here (P 5 0.009 for
rs12255372 and P 5 0.053 for rs7903146). Expression of this form in glucose-stimulated pancreatic islets cor-
related with expression of proinsulin (r
2 5 0.84–0.90, P < 0.00063). In summary, we identiﬁed a tissue-speciﬁc
pattern of alternative splicing of TCF7L2. After adjustment for multiple tests, no association between
expression of TCF7L2 in eight types of human tissue samples and T2D-associated genetic variants remained
signiﬁcant. Alternative splicing of TCF7L2 in pancreatic islets warrants future studies. GenBank Accession
Numbers: FJ010164–FJ010174.
INTRODUCTION
Common genetic variants within the transcription factor 7-like
2 gene (TCF7L2, previously known as T-cell factor 4, or
TCF-4) have been strongly associated with increased risk of
type 2 diabetes (T2D) (1). The association with T2D and
impaired function of pancreatic islets was conﬁrmed in
several genome-wide association studies (GWAS) (2–4) and
follow-up association studies (5–23). TCF7L2 is a ubiquitous
protein that belongs to a family of TCF/lymphoid enhancer
factor (LEF)) transcription factors (3). Prior to being associ-
ated with increased T2D risk, TCF7L2 was known as an
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regulator of the proliferative cellular compartment in the intes-
tine (26). Several hypotheses have been proposed to explain
how the genetic variants in TCF7L2 could increase T2D
risk. TCF7L2 might affect the ability of pancreatic islets to
produce insulin in response to stimulation by insulinotropic
intestinal hormone Glucagon-Like Peptide 1 (GLP-1) or
glucose. This hypothesis was based on the observations that
TCF7L2 could directly regulate mRNA expression of proglu-
cagon precursor in-vitro (27) and that the deletion of Tcf7l2
gene in a mouse knock-out model resulted in loss of gut epi-
thelial secretory cells that produce GLP-1 and other hormones
(26). In support of this hypothesis, it was demonstrated that
carriers of risk variants of TCF7L2 have impaired incretin
effect (28) and impaired GLP-1 stimulated insulin secretion
(16,29). It is also possible that TCF7L2 has pleiotropic tissue-
speciﬁc roles and alterations in one or more of these functions
could lead to T2D.
The most signiﬁcant genetic T2D association within
TCF7L2 was detected for two intronic single nucleotide poly-
morphisms (SNPs), rs7903146 and rs12255372, located 50 kb
from each other within a 92 kb linkage disequilibrium (LD)
block spanning exon 4 and parts of introns 3 and 4 (1–15).
All exons of TCF7L2 were sequenced in multiple patients
and controls but no coding variation was identiﬁed (1)
suggesting that T2D risk is associated with a non-coding vari-
ation. Genetic variations may affect levels of expression and
splicing architecture of mRNA transcripts (30,31) thus
several studies have tested the relationships between
TCF7L2 mRNA expression and genotypes of rs7903146 and
rs12255372 in human tissues (28,32–38). However, these
studies have been limited by the use of small sets of
samples and tissue types. Alternative exons reported for
TCF7L2 (39–41) represent a potentially important source of
functional molecular variation, yet the tissue speciﬁcity of
the alternative splicing and its relationship with genetic vari-
ation has not been fully established.
Here, we evaluated the splicing diversity and expression of
TCF7L2 in a broad range of human tissues. We provide evi-
dence that expression of alternative exons of TCF7L2 is tissue-
speciﬁc. One splicing form was unique to pancreatic islets,
pancreas and colon and not found in other tissues studied.
Expression of this form correlated with proinsulin expression
in glucose-stimulated pancreatic islets. Our study does not
provide strong evidence for association of T2D-associated
SNPs rs7903146 and rs12255372 with expression of alterna-
tively spliced forms of TCF7L2 in several tissues but points
out a potentially functional biological effect in pancreatic
islets. Future studies in larger sets of samples should conﬁrm
and explore this ﬁnding.
RESULTS
Expression of assay ‘ex7–8’ of TCF7l2 in human tissues
and test for association with rs7903146 and rs12255372
First, we measured the mRNA expression of TCF7L2 using an
assay that targeted exons 7 and 8 of the gene (assay ‘ex7–8’,
Fig. 1), and detected signals in all human tissues tested (Sup-
plementary Material, Table S1). When normalized to
expression of two housekeeping genes, b2 microglobulin
(B2M) and Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), the highest levels of expression were found in pan-
creas, colon, brain, small intestine and peripheral blood mono-
cytes. The lowest levels of expression were found in resting
and activated peripheral blood T and B cells and lymphoblas-
toid cell lines (Fig. 2 and Supplementary Material, Table S1).
Expression of TCF7L2, measured with the assay ‘ex7–8’ in
311 samples of pancreas, pancreatic islets, colon, liver, mono-
cytes and subcutaneous adipose tissue from individuals
without T2D, was not associated with genotypes of the two
most strongly T2D-associated SNPs, rs7903146 and
rs12255372 (Table 1). On the basis of the number of
samples and standard deviation in expression of assays in
each tissue tested, we estimated the detectable fold difference
between the groups of samples carrying the risk and non-risk
alleles (Table 1). In this analysis, we had 80% power (with a
type I error rate of 5%) to detect a 1.13-fold difference in
expression in colon, a 1.33-fold difference in liver, a
1.37-fold difference in monocytes, 2.06-fold in skeletal
muscle, a 2.34-fold difference in pancreatic islets and a
2.87-fold difference in adipose tissue (Table 1).
Splicing diversity of TCF7l2
Since our analysis did not reveal any association between
expression of TCF7L2 measured by assay ‘ex7–8’ and SNPs
rs7903146 and rs12255372, we hypothesized that these
genetic variants might be associated with alternative splicing.
Members of the TCF/LEF family of transcription factors use
alternative transcription start sites (TSSs) to produce function-
ally distinct proteins (42–44). To identify all TSS of TCF7L2,
we performed 50 rapid ampliﬁcation of cDNA ends (50RACE)
in an RNA pool of eight tissues (pancreas, pancreatic islets,
colon, liver, monocytes, skeletal muscles, subcutaneous
adipose tissue and lymphoblastoid cell lines). We identiﬁed
several TSS: (1) TSS1, located at 2536 bp from the ﬁrst trans-
lation start site and corresponding to RefSeq sequence
(NM_030756); (2) TSS2, located at position þ83 bp within
exon 1; (3) a cluster collectively referred as TSS3 located in
the ﬁrst intron of the gene (þ200, þ239, þ302, þ338 bp,
Fig. 3 and Supplementary Material, Table S2). Only tran-
scripts initiated from the TSS1 can be translated from a start
codon within exon 1 and produce protein isoforms with the
ß-catenin binding domain encoded by exons 1 and 2. The
next in-frame translation start site that can be used by tran-
scripts expressed from the TSS2 and TSS3, is located within
exon 3 (Fig. 3), and the resulting proteins would lack the
ß-catenin binding domain. Both the main (exon 1) and the
Figure 1. Location of expression assay ‘ex7–8’ and associated LD block with
SNPs rs7903146 and rs12255372 within TCF7L2 gene, exons are marked as
black rectangles.
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consensus sequences, ‘aaaaaaATGC’ and ‘ttcatcATGA’, com-
pared with a classical consensus site ‘gcca/gccATGG’ (45).
We also performed 30RACE in an attempt to detect alternative
splicing forms of the 30-UTRs. We did not detect any short
PCR fragments corresponding to mRNA transcripts with sig-
niﬁcantly truncated 30-UTR (data not shown). We PCR ampli-
ﬁed, cloned and sequenced full-length cDNA fragments
starting from the ﬁrst translation start site within exon 1
through the end of the transcript in exon 14 (based on
RefSeq NM_030756). We did not attempt to clone full-length
cDNAs initiated from the TSS2 because this transcription start
is embedded within exon 1 of the TSS1 form and the products
would represent a mixture of transcripts. Because of low
expression from the TSS3, further study of the transcripts
initiated from this TSS was not pursued in detail. Sequencing
of full-length cDNA clones reconﬁrmed several known
alternative exons (3a, 4a, 12, 13, 13a and 13b) and minor
in-frame inclusions of 3, 12 and 15 bp in exons 4a, 6 and 8,
respectively (39–41) (Supplementary Material, Table S2).
All sequences for full-length cDNA expression constructs
were deposited in the GenBank (FJ010164–FJ010174, Sup-
plementary Material, Table S3).
Tissue-speciﬁc expression of TCF7l2
We designed 13 expression assays (Fig. 4) that targeted the
majority of the TCF7L2 splicing forms, we observed in
human tissues. Expression of these assays was quantiﬁed in
samples from pancreas, pancreatic islets, colon, liver, mono-
cytes, skeletal muscles, subcutaneous adipose tissue and lym-
phoblastoid cell lines. Expression of an alternative exon 13b
(assay ‘ex13–13b’) was detected only in pancreatic islets,
pancreas and colon and this assay was not used in the analysis
that included all tissue samples. The expression of assay ‘ex4–
4a’ was low in all tissues and was not studied further. Sup-
plementary Material, Fig. S1 illustrates the diversity in
expression of each assay in human tissues. We performed
Principal Component Analysis (PCA) on samples from eight
tissues using four sets of expression assays (Fig. 5A–D).
We observed better discrimination between pancreatic islets
and other tissues based on expression of assays for C-terminal
Figure 2. Expression of assay ‘ex7–8’ of TCF7L2 in human tissues as fold difference compared with expression level in pancreas. TCF7L2 expression is normal-
ized to the levels of endogenous controls B2M and GAPDH (Supplementary Material, Table S1). Each tissue is represented by 1 or 2–3 pooled samples.
Table 1. Estimated detectable differences in expression of assay ‘ex7–8’ of TCF7L2 in genotype groups of rs7903146 and rs12255372 in human tissue samples
Tissue, number of samples Detectable difference,
80% power, fold
a
Detectable difference,
95% power, fold
a
rs7903146, P-value
b rs12255372, P-value
b
Pancreatic islets (n ¼ 24) 2.34 3.01 0.746 0.198
Pancreas (n ¼ 42) 1.48 1.91 0.171 1.000
Colon (n ¼ 81) 1.13 1.46 0.538 0.509
Liver (n ¼ 62) 1.33 1.71 0.998 0.857
Monocytes (n ¼ 63) 1.37 1.78 0.550 0.595
Skeletal muscles (n ¼ 25) 1.60 2.06 0.749 0.049
Subcutaneous adipose tissue (n ¼ 14) 2.87 3.70 0.523 0.539
aMinimal detectable difference in expression between groups of samples (with and without risk alleles), based on empirical standard deviation within
each group and 5% of type 1 error.
bObserved P-values, univariate linear model.
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those of assays detecting the N-terminal exons (Fig. 5A and B)
or all expression assays together (Fig. 5D and Supplementary
Material, Table S4 for relative expression of each splicing
form in human tissues).
Test for association between expression of alternatively
spliced forms of TCF7l2 and rs7903146 and rs12255372
In each tissue, we used all available covariates (age, sex, BMI,
etc.) to identify factors that could affect TCF7L2 expression
(Supplementary Material, Tables S5A–G). Since the covari-
ates were not available for all the samples and in the
absence of strong and consistent effects of any of these
factors, they were not used in the expression analysis. In pan-
creatic islets of non-T2D individuals, increasing counts of
T2D-associated risk alleles of rs12255372 were associated
with lower expression of several assays targeting C-terminal
alternative exons of TCF7L2 in up to 26 samples of human
pancreatic islets (with a signiﬁcance for univariate linear
model P ¼ 0.002 for assay ‘ex13–14’, P ¼ 0.003 for assay
‘13–13b’, P ¼ 0.010 for assay ‘ex12–13’ and P ¼ 0.022 for
assay ‘ex13–13a’ (Supplementary Material, Table S6A). In
a follow-up study, we performed expression analysis for
seven assays detecting C-terminal exons of TCF7L2 in up to
24 additional samples of pancreatic islets (Supplementary
Material, Table S6B). In the joint analysis of up to 50
samples, expression of assays ‘ex13–14’ and ‘ex13–13b’,
adjusted for sample set, remained lower in samples with
increasing counts of T2D-associated risk alleles: for assay
‘ex13–14’ P ¼ 0.018 for rs12255372 and P ¼ 0.020 for
rs7903146 (Table 2) and for assay ‘ex13–13b’ P ¼ 0.009
for rs12255372 and P ¼ 0.053 for rs7903146 (Table 2 and
Fig. 6).
In pancreas (n ¼ 46), colon (n ¼ 128), monocytes (n ¼ 65),
liver (n ¼ 62) and adipose tissue (n ¼ 14), expression of
TCF7L2 splicing forms was not associated with rs7903146
or rs12255372 (Supplementary Material, Table S6C–G). In
skeletal muscle (n ¼ 25), expression of several assays of
TCF7L2 was signiﬁcantly increased in carriers of risk alleles
of rs12255372 (P ¼ 0.049–0.005, Supplementary Material,
Table S6H) but the effect was not proportional to the counts
of risk alleles.
Test for association of expression of metabolic/endocrine
factors with genotypes of rs7903146 and rs12255372
The counts of T2D-associated risk alleles of rs12255372
and rs7903146 were not associated with mRNA expression
of several metabolic/endocrine factors important for T2D
and expressed in pancreatic islets, pancreas or colon, such
as proinsulin, proglucagon, ghrelin/obestatin, somatostatin,
pancreatic and duodenum homeobox 1 (PDX1), proliferating
cell nuclear antigen (PCNA) and vasoactive intestinal
peptide (VIP) (Supplementary Material, Table S6A, C, D).
Test for correlation between expression of proinsulin
and TCF7L2 assays in human pancreatic islets
We also correlated the expression of proinsulin and TCF7L2
assays in 23 samples of human pancreatic islets in unstimu-
lated conditions and in 12 samples incubated for 24 h in the
media with normal glucose concentration (5.5 mM) and with
high glucose concentration (16.7 mM), corresponding to
glucose blood level of T2D individuals. Expression of proinsu-
lin most strongly correlated with expression of assay
‘ex13–13b’ both in 5.5 mM glucose condition, r
2 ¼ 0.90,
P , 0.0001 and in 16.7 mM glucose condition, r
2 ¼ 0.84,
P ¼ 0.00063, but not in unstimulated samples (Table 3).
Limited by small sample set of pancreatic islets (n ¼ 12),
we did not address affects of each of SNPs on
glucose-stimulated expression.
DISCUSSION
Family-based linkage studies identiﬁed a region on chromo-
some 10q25.3 as a locus associated with T2D and ﬁne-
mapping studies within this region identiﬁed TCF7L2 as a
candidate gene for the association (1,46,47). Recent GWAS
and follow-up studies conﬁrmed several genetic variants
within the TCF7L2 gene as the strongest risk factors for devel-
opment of T2D (2–15) and impaired function of pancreatic
islets (16–22). As the ﬁrst step towards understanding the
biology of this genetic association, we performed studies on
Figure 3. Structure of the N-terminal part of TCF7L2: location of the
b-catenin binding domain encoded by exons 1 and 2, and a T2D-associated
LD block with SNPs rs7903146 and rs12255372. Shown: constitutive
exons—black rectangles, alternative exons—white rectangles; alternative tran-
scription starts sites TSS1, TSS2 and TSS3—arrows, potential translation
starts—‘ATG’.
Figure 4. Location of TaqMan expression assays within TCF7L2 gene.
Shown: constitutive exons—black rectangles, alternative exons—white rec-
tangles, expression assays—connected arrows.
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show here: (1) the expression of TCF7L2 alternative exons rep-
resents a tissue-speciﬁc signature; (2) a unique splicing form of
TCF7L2 is expressed in pancreatic islets, pancreas and colon
but not in other tissues examined here; (3) expression of this
splicing form correlates with expression of proinsulin in
glucose-stimulated pancreatic islets; (4) expression of alterna-
tively spliced forms of TCF7L2 in eight human tissues exam-
ined here is not associated with T2D-associated risk variants
rs12255372 and rs7903146.
Non-coding genetic variations have been shown to increase
disease risk by altering levels of mRNA expression and spli-
cing architecture of mRNA transcripts (30,31). In this study,
we identiﬁed several types of potentially functional splicing
Figure 5. PCA in 289 samples from 8 human tissues. (A) PCA based on three N-terminal expression assays of TCF7L2: ‘TSS1’, TSS2’ and ‘ex7–8’. (B) PCA
based on ﬁve N-terminal expression assays for TCF7L2: ‘TSS1’, ‘TSS2’, ‘TSS3’, ‘ex3a’ and ‘ex7–8’. (C) PCA based on six C-terminal expression assays for
TCF7L2: ‘ex11–13’, ‘ex11–13a’, ‘ex11–14’, ‘ex12–13’, ‘ex13–13a’ and ‘ex13–14’. (D) PCA based on all eleven expression assays for TCF7L2.
Table 2. Sample characteristics and T2F7L2 expression by genotypes of SNPs in pancreatic islets
Traits, expression assays rs7903146 rs12255372
Genotypes n Mean Fold P-value  Genotypes n Mean Fold P-value 
BMI, kg/m
2 CC 23 26.40 ref 0.812 GG 18 26.96 ref 0.562
TT 17 26.56 1.00 TG 24 26.13 0.97
TT 6 27.45 1.04 TT 4 27.80 1.03
Age, years CC 23 48.37 ref 0.510 GG 18 51.77 ref 0.328
TC 17 47.68 0.99 TG 24 46.19 0.89
TT 6 55.50 1.15 TT 4 53.93 1.04
Islets purity, % CC 22 76.95 ref 0.308 GG 17 74.02 ref 0.953
TC 16 67.94 0.88 TG 23 72.67 0.98
TT 6 72.19 0.94 TT 4 70.82 0.96
ex11–13
a CC 23 28.52 ref 0.171 GG 17 28.25 ref 0.502
TC 15 28.17 1.27 TG 23 28.59 0.79
TT 6 29.22 0.62 TT 4 28.96 0.61
ex12–13
a CC 21 27.45 ref 0.180 GG 15 27.17 ref 0.046
TC 14 27.21 1.18 TG 21 27.44 0.83
TT 5 28.46 0.50 TT 4 28.96 0.29
ex13–13a
a CC 24 29.53 ref 0.073 GG 18 29.29 ref 0.234
TC 15 29.23 1.23 TG 23 29.64 0.78
TT 6 210.79 0.42 TT 4 210.71 0.37
ex11–13a
a CC 20 26.81 ref 0.230 GG 14 26.57 ref 0.376
TC 14 26.72 1.06 TG 22 27.03 0.73
TT 6 27.56 0.59 TT 4 27.21 0.64
ex11–14
a CC 23 26.20 ref 0.156 GG 17 26.01 ref 0.559
TC 15 25.98 1.16 TG 23 26.35 0.79
TT 6 27.01 0.57 TT 4 26.57 0.68
ex13–14
a CC 23 26.52 ref 0.020 GG 17 26.15 ref 0.018
TC 15 26.65 0.91 TG 23 27.05 0.54
TT 6 28.13 0.33 TT 4 27.98 0.28
ex13–13b
a CC 24 210.90 ref 0.053 GG 16 210.48 ref 0.009
TC 12 211.56 0.63 TG 22 211.67 0.44
TT 7 212.24 0.40 TT 5 212.23 0.30
aExpression of assays, normalized to expression level of reference gene B2M, Log 2 scale, mean values are adjusted for sample set but not for multiple
tests.
 P-values for univariate linear model under an additive genetic model; in bold P-values ,0.05.
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3a and 4a encompassing the associated LD block; and alterna-
tive C-terminal exons 12, 13, 13a and 13b. Alternative TSSs
can generate mRNA transcripts encoding proteins with oppos-
ing biological functions such as proliferation versus differen-
tiation as described for LEF/TCF, c-Myc and p73 proteins
(48–50). In the case of TCF7L2, the alternative promoters
produce protein isoforms that can activate or repress the
WNT pathway dependent on the presence of b-catenin
binding domain encoded by exons 1 and 2 (51). Alternative
exons 3a and 4a are located within a protein region responsible
for interaction with a Groucho repressor protein (52). The
combinatorial tissue-speciﬁc inclusion of alternative C-
terminal exons 12, 13, 13a and 13b can activate alternative
stop codons within exons 13a, 13b or 14 and create protein
isoforms with short, medium and long reading frames
(39,41). The function of these protein isoforms is unclear;
however, only the long isoforms have binding sites for the C-
terminal binding protein (CTBP), a negative regulator of the
WNT pathway (53–55). Therefore, all alternative forms
of TCF7L2 could be functionally important. However, the
splicing variations tested here were not signiﬁcantly associated
with T2D-associated risk variants rs12255372 and rs7903146
in the human tissues tested.
A potentially biologically important observation in this
study, though not strongly supported by statistics after adjust-
ment for multiple tests, was a decrease in expression of two
expression assays of TCF7L2, ‘ex13–14’ and ‘ex13–13b’,
in pancreatic islets of carriers of T2D-associated risk variants
rs12255372 and rs7903146. This observation is in line with a
notion that depletion of TCF7L2 in pancreatic islets leads to
increased apoptosis, decrease in proliferation and glucose-
induced insulin secretion (56) found in carriers of risk variants
of TCF7L2 (19–21). The assay ‘ex13–14’ detects a splicing
form that encodes a protein with long reading frame and a
CRARF protein domain formed upon splicing of exons 13
and 14. The CRARF domain is a potent activator of the
WNT pathway and is the most conserved part of the
TCF7L2 protein in all species (54,57). The assay ‘ex13–
13b’ detects the most tissue-speciﬁc splicing form of
TCF7L2 expressed in pancreatic islets, colon and at a lower
level in pancreas but not in multiple samples representing
liver, skeletal muscles, adipocytes, monocytes or lymphoblas-
toid cell lines tested here. Expression of this form in pancreatic
islets was 30-fold higher than in pancreas (Supplementary
Material, Fig. S3). In pancreatic islets cultured at normal
(5.5 mM) or high glucose (16.7 mM) conditions, mRNA
expression of proinsulin most strongly correlated with
expression of assay ‘ex13–13b’ (r
2 ¼ 0.84–0.90, P ,
0.00063), but not with other assays of TCF7L2. Perhaps, the
splicing form detected by this assay marks a speciﬁc glucose-
sensing or secretory cell type within pancreatic islets. Limited
by a small sample set of glucose-induced islets (n ¼ 12), we
did not address effects of these SNPs on correlation with
insulin expression. We did not observe association between
counts of risk alleles of rs7903146 and rs12255372 and
mRNA levels of proinsulin, proglucagon (the precursor of
the insulinotropic hormone GLP-1) and several other meta-
bolic/endocrine factors in pancreatic islets, pancreas and
colon but this does not exclude the possibility that protein
expression and secretion of these factors may be affected in
carriers of the TCF7L2 risk variants.
The reports on association of TCF7L2 expression in human
pancreatic islets and genotypes of T2D-associated variants
within TCF7L2 are few. Lyssenko et al. (28) used the assay
‘ex7–8’ of TCF7L2 in 15 samples of human pancreatic
islets and reported a signiﬁcantly higher expression in carriers
of rs7903146 risk genotypes. Osmark et al. (38) addressed the
expression of several splicing forms in a set of 17 pancreatic
islets but did not observe any association between expression
of several TCF7L2 assays and genotypes of rs7903146. For
several assays that targeted the same splicing forms (‘ex3a–
4’, ‘ex11–14’, ‘ex11–13’, ‘ex11–13a’) we see the same
results as reported by Osmark et al. The assays ‘ex13–14’
and ‘ex13–13b’ whose expression showed some evidence
for association with T2D-associated variants of TCF7L2 in
our study have not been previously used in any tissue.
Additionally, we used larger sample sets for each tissue and
for the ﬁrst time studied expression of TCF7L2 in tissues
such as pancreas, peripheral blood monocytes and colon.
We recognize the limitations of the approaches used in this
study. Human tissue samples consist of multiple cell types that
Figure 6. Expression of assay ‘ex13–13b’ in human pancreatic islets by
rs12255372 and rs7903146 genotypes. Normalized expression of assay
‘ex13–13b’ is shown in Log 2 scale relative to a mean value of the whole
set. Association was tested with univariate linear regression under an additive
genetic model for SNPs and with adjustment for two sample sets.
Table 3. Correlation between mRNA expression of proinsulin and TCF7L2 in
pancreatic islets
TCF7L2 assay Unstimulated,
n ¼ 23
Stimulated
5.5 mM glucose,
n ¼ 12
Stimulated
16.7 mM
glucose, n ¼ 12
r
2 P-value r
2 P-value r
2 P-value
TSS3 20.296 NS 0.14 NS 0.17 NS
Ex3a–4 20.407 NS 0.35 NS 0.29 NS
Ex11–13 20.333 NS 0.61 0.035 0.57 NS
Ex11–13a 20.481 0.020 0.46 NS 0.29 NS
Ex11–14 20.436 0.038 0.63 0.028 0.46 NS
Ex12–13 20.021 NS 0.73 0.007 0.54 NS
Ex13–13a 20.158 NS 0.69 0.013 0.46 NS
Ex13–14 20.292 NS 0.53 NS 0.44 NS
Ex13–13b 0.189 NS 0.90 <0.0001 0.84 0.00063
r
2—Pearson correlation coefﬁcient, NS—not signiﬁcant, in bold—
signiﬁcant correlations, P , 0.05; Glucose-stimulated islets were
incubated in 5.5 or 16.7 mM glucose media at 378C for 24 h.
3800 Human Molecular Genetics, 2009, Vol. 18, No. 20can exhibit diverse pattern of TCF7L2 expression. Tissue
biopsies were taken during surgeries preceded by fasting and
stress, thus these samples may not represent optimal physio-
logical conditions for studies on T2D-related phenotypes.
We attempted to identify and quantify the majority of splicing
variation within TCF7L2. However, the analysis did not cover
several minor splicing variations and yet unknown splicing
forms of TCF7L2 that can exist and contribute to disease.
The P-values for association between the counts of
T2D-associated alleles and TCF7L2 expression were not
adjusted for multiple testing. A Bonferroni correction would
be overly stringent given the correlation between the 13
assays within each tissue. Our goal was to identify potential
biologically important differences that should be tested in
other sets of samples and with additional methods. We under-
stand that with relatively small sample sets representing each
tissue type, some of our results might be false-positives or
false-negatives. Larger numbers of samples from each tissue
type and, particularly, pancreatic islets, would increase the
power to detect association between TCF7L2 expression and
TCF7L2 SNP variants. Risk variants of TCF7L2 SNPs might
be associated with several types of molecular changes relevant
for T2D and our study addressed only one of these types,
mRNA expression of alternative splicing forms. It is possible
that there might be other important molecular phenotypes of
TCF7L2 yet to be identiﬁed and examined. The C-terminal
exons of TCF7L2 are located .100 kb away from the associ-
ated LD block. How the associated DNA variants can affect
the mRNA expression and splicing at this distance, is not
yet understood. A potential mechanism could be related to
long-distance co-transcriptional regulation of mRNA
expression and splicing (58,59).
In conclusion, our ﬁndings provide new evidence of tissue-
speciﬁc patterns of alternative splicing of TCF7L2. Moreover,
we provide the ﬁrst suggestive evidence that decreased
expression of one ubiquitous and one rare tissue-speciﬁc
alternative splicing forms of the gene in pancreatic islets
may be associated with T2D-associated genetic variants of
TCF7L2. Future studies should conﬁrm and explore the
observed association between genetic variation within
TCF7L2, tissue-speciﬁc alternative splicing and risk of T2D.
MATERIALS AND METHODS
Tissue samples
Puriﬁed human pancreatic islets in the US set were obtained
from the Islet Cell Resource Centers (IRB exemption
number 3072) and the National Disease Research Interchange
(IRB exemption number 3269) under IRB exemption by the
National Institutes of Health Ofﬁce of Human Subjects
Research. Pancreatic islets were provided by Washington Uni-
versity, St. Louis, MO, USA; City of Hope National Medical
Center, Duarte, CA, USA; University of Miami, Miami, FL,
USA and the Joslin Diabetes Center, Boston, MA, USA. Infor-
mation on age, sex, BMI, islets purity and viability, duration of
cold ischemic time (time between pancreas removal and islet
preparation), cause of death, T2D status and CMV infection
was available for these samples. Pancreatic islets in the
Swedish set were provided by the Nordic Network for Clinical
Islet Transplantation by the courtesy of Dr Olle Korsgren at
Uppsala University, Sweden and Dr Jalal Taneera at the
Human Tissue laboratory at Lund University Diabetes
Centre, Sweden.
Human pancreas, colon and liver samples were biopsies
obtained from the University of Minnesota Tissue Procure-
ment Center, Minneapolis, MN, USA, and Children’s Hospi-
tal, Boston, MA, USA. For the majority of these samples
clinical reports indicating primary diagnosis, T2D status,
age, sex and BMI were available. All tissue biopsies were non-
malignant tissues as conﬁrmed by pathology reports. Skeletal
muscles biopsies were collected from healthy individuals and
patients with Duchenne or Becker Muscular dystrophy at the
Research Center for Genetic Medicine, Children’s National
Medical Center, Washington, DC, USA. Information about
age, sex, BMI and disease status was available for these
samples. Samples of fresh blood were from anonymous
human blood donors and information about age and sex of
the subjects were provided by the NIH Clinical Center Div-
ision of Transfusion Medicine. Monocytes were separated
from fresh blood with CD14
þ-coated magnetic MicroBeads
with AutoMacs (Miltenyi Biotec). Frozen samples of human
subcutaneous adipose tissue were purchased from Zen-Bio,
Inc. and information on age, sex, BMI and T2D status was
available for these samples. IRB approval for de-identiﬁed
tissues was obtained from all Institutions involved. All
samples with known T2D were excluded (ﬁve samples in the
whole set of all tissues). 293T (human embryonic kidney),
HeLa (human cervical carcinoma), HepG2 (human hepatocellu-
lar carcinoma) were purchased from ATCC (the American
Type Culture Collection) and lymphoblastoid cell lines from
CEPH (Centre d’ Etude du Polymorphisme Humain) individ-
uals were purchased from Coriell cell repositories.
Glucose-stimulated pancreatic islets
Twelve samples from the US set were split in six aliquots
each. Three aliquots were incubated in CMRL-1066 cell
culture media with 5.5 mM glucose while other three aliquots
of the same samples were incubated with CMRL-1066 cell
culture media with 16.7 mM glucose for 24 h.
Preparation of DNA and RNA
DNA from tissue samples was prepared with DNeasy Kit
(Qiagen) except for adipose tissue where DNA was recovered
after RNA preparation according to Trizol protocol (Invitro-
gen). RNA was prepared with Trizol (Invitrogen) followed
by RNeasy kit (Qiagen). RNA from the second set of pancrea-
tic islets RNA was isolated using the AllPrep DNA/RNA Mini
Kit (Qiagen). No sign of RNA degradation was observed using
agarose gel electrophoresis and Experion DNA 1 K gel chips
(Bio-Rad). RNA samples from all additional human tissues
and cDNA from puriﬁed blood fractions (Multiple Tissue
cDNA panels) were purchased from Clontech.
Genotyping
Genotyping was performed with an allelic-discrimination
TaqMan assays for rs12255372 and rs7903146 and the Univer-
Human Molecular Genetics, 2009, Vol. 18, No. 20 3801sal Genotyping Master Mix (Applied Biosystems). Alterna-
tively or as an additional control, genotyping was performed
by primer extension method using a Sequenom MALDI-TOF
platform (Broad Institute).
cDNA preparation and qPCR
cDNA was prepared in a 20 ml volume with 500 ng of DNase-
treated total RNA with use of random hexamers and Super-
script III reverse transcriptase (Invitrogen) (set 1) or with the
Qiagen Omniscript RT kit with 1 mM dT18 oligomer and
3 mM random hexamer primers (set 2 (38)). DNA was
diluted with water to 200 ml and an equivalent of 5–10 ng
of total RNA was used for each reaction (except for lympho-
blastoid cell lines where 2 mg of total RNA was used as a start-
ing amount). All reactions were run in three or four technical
replicates. Standard deviations of below 0.2 Ct between the
replicates were acceptable for high-expressing assays and
0.5 Ct for low-expressing assays. Endogenous controls B2M
(ß-2 microglobulin) or GAPDH (Glyceraldehyde-3-phosphate
dehydrogenase) were measured from the same cDNA prep-
arations with expression assays Hs00187842_m1 for B2M
and 4333764F for GAPDH (Applied Biosystems). All
primers for custom-designed assays were created to amplify
only from cDNA and TaqMan probes were placed on the junc-
tions between speciﬁc exons (Supplementary Material,
Table S7 for primer sequences and assay information). All
quantitative PCR reactions were performed in a 10 ml
volume using the 7900 Real-Time PCR System (ABI) in
384 well plates. Universal Expression Master Mix was used
for all expression studies with TaqMan probes according to
standard conditions (Applied Biosystems). The reactions
with 2 SYBR Green PCR mix (Qiagen) and speciﬁc
primers were carried out for 15 min at 958C, followed by 40
cycles of 15 s at 958C, 15 sec at 598C and 45 s at 728C.
Post-PCR melting curve analysis was used after each run.
Initially, gel-puriﬁed PCR fragments were sequenced to
ensure the speciﬁcity of ampliﬁcation and correct splicing.
Data analysis
Values from three to four technical replicates for each
expression assay were averaged and normalized to the
expression levels of BM2 and GAPDH run in separate reac-
tions from the same cDNA preparation. Relative differences
in expression were calculated according to formula: dCt ¼
Ctreference 2 Cttarget, where ‘reference’ represents levels of
expression (Ct values) of B2M, GAPDH or both genes and
‘target’ represents level of expression of TCF7L2 assays;
negative Ct means that a target is expressed lower than a refer-
ence gene; fold difference in expression between a reference
and a target can be calculated as 2
(dCt)
. Within each tissue
and assay, the log-transformed expression values were tested
for normality. The associations between speciﬁed variables
were tested using univariate linear model with inclusion of
covariates where indicated (SPSS 16.0 software). The
SNP-TCF7L2 expression or SNP-T2D related gene expression
analyses were used according to an additive genetic model.
The PCA analysis on mean-centered expression values for
selected assays was performed with GenEx software
(MultiD). We estimated the fold-difference in gene expression
between samples with and without the T2D associated risk
genotype that could be detected with 80 or 95% power with
a type 1 error rate of 5%. For the power calculations for
assay ‘ex7–8’ have been performed with observed standard
deviation for this assay in each tissue and the number of
samples with and without T2D associated risk genotypes (Stat-
Mate software, GraphPad). The power analysis differs from
our regression analysis of gene expression and allele count,
but is a good approximation when the less frequent genotype
homozygote samples are rare.
For each sample of glucose-stimulated pancreatic islets,
expression values of technical triplicates were averaged and
then normalized to expression of endogenous control, B2M.
The normalized values were averaged for three aliquots of
the same samples. Therefore, for each sample and experimen-
tal condition expression was measured nine times. The
Pearson correlation coefﬁcients between expression of
TCF7L2 assays and proinsulin were calculated with SPSS
16.0.
50RACE and analysis of splicing forms
50RACE cDNA from multiple tissues was prepared from 200
to 500 ng of total RNA with use of the BD SMART RACE
cDNA ampliﬁcation kit (Clontech). PCR fragments were
ampliﬁed with universal primers included in the kit and
several gene-speciﬁc speciﬁc primers. PCR fragments were
gel-puriﬁed (Qiaquick, Qiagen) and sequenced with BD Ter-
minator chemistry (Applied Biosystems). The full-length
cDNA fragments from the ﬁrst ATG translation start site in
exon 1 and to the most distant stop codon within exon 14
were ampliﬁed by a proof-reading KOD polymerase
(Novagen), cloned into pFC8A vector (Promega) and multiple
individual clones were sequenced. Expression constructs for
TCF7L2 splicing forms are available upon request.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
A special thank you to Marjorie Carlson and Mona Sva ¨rdh for
technical assistance, Sara Bowell and Drs Ralph Powell, Amy
Skubitz, Stephen Schmechel, and Charlie Moldow for facili-
tation of the access to tissue samples through the University
of Minnesota Tissue Procurement Facility, to Islet Cell
Resource Centers and the National Disease Research Inter-
change Network for human islets. Human islets (Swedish
cohort) were provided by the Nordic Network for Clinical
Islet Transplantation by the courtesy of Dr Olle Korsgren at
Uppsala University, Sweden and Dr Jalal Taneera at the
Human Tissue laboratory at Lund University Diabetes
Centre, Sweden. LPO was a Wenner-Gren Fellow.
Conﬂict of Interest statement. None declared.
3802 Human Molecular Genetics, 2009, Vol. 18, No. 20FUNDING
The project was supported by NIH grant 1R21DK078029-01
(JH), Intramural Research Programs of NHGRI and NCI of
NIH. Work at LUDC was funded by grants from the
Swedish Research Council, the Wallenberg Foundation and
the Novo Nordisk Foundation. Funding to pay the Open
Access publication charges for this article was provided by
the intramural research program of NCI/NIH.
REFERENCES
1. Grant, S.F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R.,
Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V.,
Helgadottir, A. et al. (2006) Variant of transcription factor 7-like 2
(TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet., 38, 320–323.
2. Scott, L.J., Mohlke, K.L., Bonnycastle, L.L., Willer, C.J., Li, Y., Duren,
W.L., Erdos, M.R., Stringham, H.M., Chines, P.S., Jackson, A.U. et al.
(2007) A genome-wide association study of type 2 diabetes in Finns
detects multiple susceptibility variants. Science, 316, 1341–1345.
3. Saxena, R., Voight, B.F., Lyssenko, V., Burtt, N.P., de Bakker, P.I., Chen,
H., Roix, J.J., Kathiresan, S., Hirschhorn, J.N., Daly, M.J. et al. (2007)
Genome-wide association analysis identiﬁes loci for type 2 diabetes and
triglyceride levels. Science, 316, 1331–1336.
4. Zeggini, E., Weedon, M.N., Lindgren, C.M., Frayling, T.M., Elliott, K.S.,
Lango, H., Timpson, N.J., Perry, J.R., Rayner, N.W., Freathy, R.M. et al.
(2007) Replication of genome-wide association signals in UK samples
reveals risk loci for type 2 diabetes. Science, 316, 1336–1341.
5. Zhang, C., Qi, L., Hunter, D.J., Meigs, J.B., Manson, J.E., van Dam, R.M.
and Hu, F.B. (2006) Variant of transcription factor 7-like 2 (TCF7L2)
gene and the risk of type 2 diabetes in large cohorts of U.S. women and
men. Diabetes, 55, 2645–2648.
6. van Vliet-Ostaptchouk, J.V., Shiri-Sverdlov, R., Zhernakova, A.,
Strengman, E., van Haeften, T.W., Hofker, M.H. and Wijmenga, C.
(2007) Association of variants of transcription factor 7-like 2 (TCF7L2)
with susceptibility to type 2 diabetes in the Dutch Breda cohort.
Diabetologia, 50, 59–62.
7. Scott, L.J., Bonnycastle, L.L., Willer, C.J., Sprau, A.G., Jackson, A.U.,
Narisu, N., Duren, W.L., Chines, P.S., Stringham, H.M., Erdos, M.R. et al.
(2006) Association of transcription factor 7-like 2 (TCF7L2) variants with
type 2 diabetes in a Finnish sample. Diabetes, 55, 2649–2653.
8. Saxena, R., Gianniny, L., Burtt, N.P., Lyssenko, V., Giuducci, C., Sjogren,
M., Florez, J.C., Almgren, P., Isomaa, B., Orho-Melander, M. et al. (2006)
Common single nucleotide polymorphisms in TCF7L2 are reproducibly
associated with type 2 diabetes and reduce the insulin response to glucose
in nondiabetic individuals. Diabetes, 55, 2890–2895.
9. Mayans, S., Lackovic, K., Lindgren, P., Ruikka, K., Agren, A., Eliasson,
M. and Holmberg, D. (2007) TCF7L2 polymorphisms are associated with
type 2 diabetes in northern Sweden. Eur. J. Hum. Genet., 15, 342–346.
10. Marzi, C., Huth, C., Kolz, M., Grallert, H., Meisinger, C., Wichmann,
H.E., Rathmann, W., Herder, C. and Illig, T. (2007) Variants of the
transcription factor 7-like 2 gene (TCF7L2) are strongly associated with
type 2 diabetes but not with the metabolic syndrome in the MONICA/
KORA surveys. Horm. Metab. Res., 39, 46–52.
11. Humphries, S.E., Gable, D., Cooper, J.A., Ireland, H., Stephens, J.W.,
Hurel, S.J., Li, K.W., Palmen, J., Miller, M.A., Cappuccio, F.P. et al.
(2006) Common variants in the TCF7L2 gene and predisposition to type 2
diabetes in UK European Whites, Indian Asians and Afro-Caribbean men
and women. J. Mol. Med., 84, 1–10.
12. Helgason, A., Palsson, S., Thorleifsson, G., Grant, S.F., Emilsson, V.,
Gunnarsdottir, S., Adeyemo, A., Chen, Y., Chen, G., Reynisdottir, I. et al.
(2007) Reﬁning the impact of TCF7L2 gene variants on type 2 diabetes
and adaptive evolution. Nat. Genet., 39, 218–225.
13. Groves, C.J., Zeggini, E., Minton, J., Frayling, T.M., Weedon, M.N.,
Rayner, N.W., Hitman, G.A., Walker, M., Wiltshire, S., Hattersley, A.T.
et al. (2006) Association analysis of 6,736 U.K. subjects provides
replication and conﬁrms TCF7L2 as a type 2 diabetes susceptibility gene
with a substantial effect on individual risk. Diabetes, 55, 2640–2644.
14. Damcott, C.M., Pollin, T.I., Reinhart, L.J., Ott, S.H., Shen, H., Silver,
K.D., Mitchell, B.D. and Shuldiner, A.R. (2006) Polymorphisms in the
transcription factor 7-like 2 (TCF7L2) gene are associated with type 2
diabetes in the Amish: replication and evidence for a role in both insulin
secretion and insulin resistance. Diabetes, 55, 2654–2659.
15. Chandak, G.R., Janipalli, C.S., Bhaskar, S., Kulkarni, S.R., Mohankrishna,
P., Hattersley, A.T., Frayling, T.M. and Yajnik, C.S. (2007) Common
variants in the TCF7L2 gene are strongly associated with type 2 diabetes
mellitus in the Indian population. Diabetologia, 50, 63–67.
16. Schafer, S.A., Tschritter, O., Machicao, F., Thamer, C., Stefan, N.,
Gallwitz, B., Holst, J.J., Dekker, J.M., t’Hart, L.M., Nijpels, G. et al.
(2007) Impaired glucagon-like peptide-1-induced insulin secretion in
carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.
Diabetologia, 50, 2443–2450.
17. Raitakari, O.T., Ronnemaa, T., Huupponen, R., Viikari, L., Fan, M.,
Marniemi, J., Hutri-Kahonen, N., Viikari, J.S. and Lehtimaki, T. (2007)
Variation of the transcription factor 7-like 2 (TCF7L2) gene predicts
impaired fasting glucose in healthy young adults: the Cardiovascular Risk
in Young Finns Study. Diabetes Care, 30, 2299–2301.
18. Palmer, N.D., Lehtinen, A.B., Langefeld, C.D., Campbell, J.K., Haffner,
S.M., Norris, J.M., Bergman, R.N., Goodarzi, M.O., Rotter, J.I. and
Bowden, D.W. (2008) Association of TCF7L2 gene polymorphisms with
reduced acute insulin response in Hispanic Americans. J. Clin.
Endocrinol. Metab., 93, 304–309.
19. Munoz, J., Lok, K.H., Gower, B.A., Fernandez, J.R., Hunter, G.R.,
Lara-Castro, C., De Luca, M. and Garvey, W.T. (2006) Polymorphism in
the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced
insulin secretion in nondiabetic women. Diabetes, 55, 3630–3634.
20. Watanabe, R.M., Allayee, H., Xiang, A.H., Trigo, E., Hartiala, J.,
Lawrence, J.M. and Buchanan, T.A. (2007) Transcription factor 7-like 2
(TCF7L2) is associated with gestational diabetes mellitus and interacts
with adiposity to alter insulin secretion in Mexican Americans. Diabetes,
56, 1481–1485.
21. Wang, J., Kuusisto, J., Vanttinen, M., Kuulasmaa, T., Lindstrom, J.,
Tuomilehto, J., Uusitupa, M. and Laakso, M. (2007) Variants of
transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2
diabetes in the Finnish Diabetes Prevention Study and are associated with
impaired glucose regulation and impaired insulin secretion. Diabetologia,
50, 1192–1200.
22. Stolerman, E.S., Manning, A.K., McAteer, J.B., Fox, C.S., Dupuis, J.,
Meigs, J.B. and Florez, J.C. (2009) TCF7L2 variants are associated with
increased proinsulin/insulin ratios but not obesity traits in the Framingham
Heart Study. Diabetologia, 52, 614–620.
23. Stancakova, A., Kuulasmaa, T., Paananen, J., Jackson, A.U., Bonnycastle,
L.L., Collins, F.S., Boehnke, M., Kuusisto, J. and Laakso, M. (2009)
Association of 18 conﬁrmed susceptibility loci for type 2 diabetes with
indices of insulin release, proinsulin conversion, and insulin sensitivity in
5 327 non-diabetic Finnish men. Diabetes (Epub ahead of print).
24. Clevers, H. and van de Wetering, M. (1997) TCF/LEF factor earn their
wings. Trends Genet., 13, 485–489.
25. Brantjes, H., Barker, N., van Es, J. and Clevers, H. (2002) TCF: Lady
Justice casting the ﬁnal verdict on the outcome of Wnt signalling. Biol.
Chem., 383, 255–261.
26. Korinek, V., Barker, N., Moerer, P., van Donselaar, E., Huls, G., Peters,
P.J. and Clevers, H. (1998) Depletion of epithelial stem-cell
compartments in the small intestine of mice lacking Tcf-4. Nat. Genet.,
19, 379–383.
27. Yi, F., Brubaker, P.L. and Jin, T. (2005) TCF-4 mediates cell type-speciﬁc
regulation of proglucagon gene expression by beta-catenin and glycogen
synthase kinase-3beta. J. Biol. Chem., 280, 1457–1464.
28. Lyssenko, V., Lupi, R., Marchetti, P., Del Guerra, S., Orho-Melander, M.,
Almgren, P., Sjogren, M., Ling, C., Eriksson, K.F., Lethagen, A.L. et al.
(2007) Mechanisms by which common variants in the TCF7L2 gene
increase risk of type 2 diabetes. J. Clin. Invest., 117, 2155–2163.
29. Pilgaard, K., Jensen, C.B., Schou, J.H., Lyssenko, V., Wegner, L., Brons,
C., Vilsboll, T., Hansen, T., Madsbad, S., Holst, J.J. et al. (2009) The T
allele of rs7903146 TCF7L2 is associated with impaired insulinotropic
action of incretin hormones, reduced 24 h proﬁles of plasma insulin and
glucagon, and increased hepatic glucose production in young healthy men.
Diabetologia, 52, 1298–1307.
30. Zhang, W., Duan, S., Bleibel, W.K., Wisel, S.A., Huang, R.S., Wu, X.,
He, L., Clark, T.A., Chen, T.X., Schweitzer, A.C. et al. (2008)
Identiﬁcation of common genetic variants that account for transcript
isoform variation between human populations. Hum. Genet., 125, 81–93.
31. Graham, R.R., Kozyrev, S.V., Baechler, E.C., Reddy, M.V., Plenge, R.M.,
Bauer, J.W., Ortmann, W.A., Koeuth, T., Gonzalez Escribano, M.F.,
Human Molecular Genetics, 2009, Vol. 18, No. 20 3803Pons-Estel, B. et al. (2006) A common haplotype of interferon regulatory
factor 5 (IRF5) regulates splicing and expression and is associated with
increased risk of systemic lupus erythematosus. Nat. Genet., 38, 550–555.
32. Ahlzen, M., Johansson, L.E., Cervin, C., Tornqvist, H., Groop, L. and
Ridderstrale, M. (2008) Expression of the transcription factor 7-like 2
gene (TCF7L2) in human adipocytes is down regulated by insulin.
Biochem. Biophys. Res. Commun., 370, 49–52.
33. Wegner, L., Hussain, M.S., Pilgaard, K., Hansen, T., Pedersen, O., Vaag,
A. and Poulsen, P. (2008) Impact of TCF7L2 rs7903146 on Insulin
Secretion and Action in Young and Elderly Danish Twins. J. Clin.
Endocrinol. Metab., 93, 4013–4019.
34. Elbein, S.C., Chu, W.S., Das, S.K., Yao-Borengasser, A., Hasstedt, S.J.,
Wang, H., Rasouli, N. and Kern, P.A. (2007) Transcription factor 7-like 2
polymorphisms and type 2 diabetes, glucose homeostasis traits and gene
expression in US participants of European and African descent.
Diabetologia, 50, 1621–1630.
35. Cauchi, S., Meyre, D., Dina, C., Choquet, H., Samson, C., Gallina, S.,
Balkau, B., Charpentier, G., Pattou, F., Stetsyuk, V. et al. (2006)
Transcription factor TCF7L2 genetic study in the French population:
expression in human beta-cells and adipose tissue and strong association
with type 2 diabetes. Diabetes, 55, 2903–2908.
36. Huertas-Vazquez, A., Plaisier, C., Weissglas-Volkov, D., Sinsheimer, J.,
Canizales-Quinteros, S., Cruz-Bautista, I., Nikkola, E.,
Herrera-Hernandez, M., Davila-Cervantes, A., Tusie-Luna, T. et al.
(2008) TCF7L2 is associated with high serum triacylglycerol and
differentially expressed in adipose tissue in families with familial
combined hyperlipidaemia. Diabetologia, 51, 62–69.
37. Hindle, A.K., Brody, F., Tevar, R., Kluk, B., Hill, S., McCaffrey, T. and
Fu, S. (2008) TCF7L2 expression in diabetic patients undergoing bariatric
surgery. Surg. Endosc., 23, 1292–1297.
38. Osmark, P., Hansson, O., Jonsson, A., Ronn, T., Groop, L. and Renstrom,
E. (2009) Unique splicing pattern of the TCF7L2 gene in human
pancreatic islets. Diabetologia, 52, 850–854.
39. Duval, A., Busson-Leconiat, M., Berger, R. and Hamelin, R. (2000)
Assignment of the TCF-4 gene (TCF7L2) to human chromosome band
10q25.3. Cytogenet. Cell Genet., 88, 264–265.
40. Howng, S.L., Huang, F.H., Hwang, S.L., Lieu, A.S., Sy, W.D., Wang, C.
and Hong, Y.R. (2004) Differential expression and splicing isoform
analysis of human Tcf-4 transcription factor in brain tumors.
Int. J. Oncol., 25, 1685–1692.
41. Shiina, H., Igawa, M., Breault, J., Ribeiro-Filho, L., Pookot, D., Urakami,
S., Terashima, M., Deguchi, M., Yamanaka, M., Shirai, M. et al. (2003)
The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway,
and apoptosis in renal cell carcinoma. Clin. Cancer Res., 9, 2121–2132.
42. Van de Wetering, M., Castrop, J., Korinek, V. and Clevers, H. (1996)
Extensive alternative splicing and dual promoter usage generate Tcf-1
protein isoforms with differential transcription control properties. Mol.
Cell Biol., 16, 745–752.
43. Hovanes, K., Li, T.W. and Waterman, M.L. (2000) The human LEF-1
gene contains a promoter preferentially active in lymphocytes and
encodes multiple isoforms derived from alternative splicing. Nucleic
Acids Res., 28, 1994–2003.
44. Hovanes, K., Li, T.W., Munguia, J.E., Truong, T., Milovanovic, T.,
Lawrence Marsh, J., Holcombe, R.F. and Waterman, M.L. (2001)
Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are
selectively expressed in colon cancer. Nat. Genet., 28, 53–57.
45. Kozak, M. (1987) An analysis of 50-noncoding sequences from 699
vertebrate messenger RNAs. Nucleic Acids Res., 15, 8125–8148.
46. Reynisdottir, I., Thorleifsson, G., Benediktsson, R., Sigurdsson, G.,
Emilsson, V., Einarsdottir, A.S., Hjorleifsdottir, E.E., Orlygsdottir, G.T.,
Bjornsdottir, G.T., Saemundsdottir, J. et al. (2003) Localization of a
susceptibility gene for type 2 diabetes to chromosome 5q34-q35.2.
Am. J. Hum. Genet., 73, 323–335.
47. Duggirala, R., Blangero, J., Almasy, L., Dyer, T.D., Williams, K.L.,
Leach, R.J., O’Connell, P. and Stern, M.P. (1999) Linkage of type 2
diabetes mellitus and of age at onset to a genetic location on chromosome
10q in Mexican Americans. Am. J. Hum. Genet., 64, 1127–1140.
48. Li, T.W., Ting, J.H., Yokoyama, N.N., Bernstein, A., van de Wetering, M.
and Waterman, M.L. (2006) Wnt activation and alternative promoter
repression of LEF1 in colon cancer. Mol. Cell Biol., 26, 5284–5299.
49. Benassayag, C., Montero, L., Colombie, N., Gallant, P., Cribbs, D. and
Morello, D. (2005) Human c-Myc isoforms differentially regulate cell
growth and apoptosis in Drosophila melanogaster. Mol. Cell Biol., 25,
9897–9909.
50. Zaika, A.I., Slade, N., Erster, S.H., Sansome, C., Joseph, T.W., Pearl, M.,
Chalas, E. and Moll, U.M. (2002) DeltaNp73, a dominant-negative
inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
J. Exp. Med., 196, 765–780.
51. Korinek, V., Barker, N., Morin, P.J., van Wichen, D., de Weger, R.,
Kinzler, K.W., Vogelstein, B. and Clevers, H. (1997) Constitutive
transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon
carcinoma. Science, 275, 1784–1787.
52. Brantjes, H., Roose, J., van De Wetering, M. and Clevers, H. (2001) All
Tcf HMG box transcription factors interact with Groucho-related
co-repressors. Nucleic Acids Res., 29, 1410–1419.
53. Fang, M., Li, J., Blauwkamp, T., Bhambhani, C., Campbell, N. and
Cadigan, K.M. (2006) C-terminal-binding protein directly activates and
represses Wnt transcriptional targets in Drosophila. EMBO J., 25, 2735–
2745.
54. Atcha, F.A., Syed, A., Wu, B., Hoverter, N.P., Yokoyama, N.N., Ting,
J.H., Munguia, J.E., Mangalam, H.J., Marsh, J.L. and Waterman, M.L.
(2007) A unique DNA binding domain converts T-cell factors into strong
Wnt effectors. Mol. Cell Biol., 27, 8352–8363.
55. Tang, W., Dodge, M., Gundapaneni, D., Michnoff, C., Roth, M. and Lum,
L. (2008) A genome-wide RNAi screen for Wnt/beta-catenin pathway
components identiﬁes unexpected roles for TCF transcription factors in
cancer. Proc. Natl. Acad Sci. USA, 105, 9697–9702.
56. Shu, L., Sauter, N.S., Schulthess, F.T., Matveyenko, A.V., Oberholzer, J.
and Maedler, K. (2008) Transcription factor 7-like 2 regulates beta-cell
survival and function in human pancreatic islets. Diabetes, 57, 645–653.
57. Atcha, F.A., Munguia, J.E., Li, T.W., Hovanes, K. and Waterman, M.L.
(2003) A new beta-catenin-dependent activation domain in T cell factor.
J. Biol. Chem., 278, 16169–16175.
58. Listerman, I., Sapra, A.K. and Neugebauer, K.M. (2006) Cotranscriptional
coupling of splicing factor recruitment and precursor messenger RNA
splicing in mammalian cells. Nat. Struct. Mol. Biol., 13, 815–822.
59. Kornblihtt, A.R., de la Mata, M., Fededa, J.P., Munoz, M.J. and Nogues,
G. (2004) Multiple links between transcription and splicing. RNA, 10,
1489–1498.
3804 Human Molecular Genetics, 2009, Vol. 18, No. 20